[go: up one dir, main page]

AU2001253673A1 - Inhibitors of retroviral protease as inducers of reversible insulin resistance in vitro and in vivo - Google Patents

Inhibitors of retroviral protease as inducers of reversible insulin resistance in vitro and in vivo

Info

Publication number
AU2001253673A1
AU2001253673A1 AU2001253673A AU5367301A AU2001253673A1 AU 2001253673 A1 AU2001253673 A1 AU 2001253673A1 AU 2001253673 A AU2001253673 A AU 2001253673A AU 5367301 A AU5367301 A AU 5367301A AU 2001253673 A1 AU2001253673 A1 AU 2001253673A1
Authority
AU
Australia
Prior art keywords
inducers
reversible
vitro
vivo
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253673A
Other languages
English (en)
Inventor
Michael Mueckler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Publication of AU2001253673A1 publication Critical patent/AU2001253673A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001253673A 2000-04-19 2001-04-19 Inhibitors of retroviral protease as inducers of reversible insulin resistance in vitro and in vivo Abandoned AU2001253673A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19852400P 2000-04-19 2000-04-19
US60198524 2000-04-19
PCT/US2001/012697 WO2001081926A1 (fr) 2000-04-19 2001-04-19 Inhibiteurs de protease retrovirale en tant qu'inducteurs de resistance reversible a l'insuline, in vitro et in vivo

Publications (1)

Publication Number Publication Date
AU2001253673A1 true AU2001253673A1 (en) 2001-11-07

Family

ID=22733733

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253673A Abandoned AU2001253673A1 (en) 2000-04-19 2001-04-19 Inhibitors of retroviral protease as inducers of reversible insulin resistance in vitro and in vivo

Country Status (3)

Country Link
US (1) US6440659B1 (fr)
AU (1) AU2001253673A1 (fr)
WO (1) WO2001081926A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528037B2 (en) * 2000-10-11 2003-03-04 Telik, Inc. Method for determining whether a compound is an insulin receptor kinase activator
KR20030031189A (ko) * 2000-10-11 2003-04-18 텔리크 인코포레이티드 Ｈｉｖ 프로테아제 저해제를 이용한 ｈｉｖ 감염 치료에기인한 인간의 대사 장애 치료용 인슐린 수용체 활성인자
US20030235851A1 (en) * 2002-04-19 2003-12-25 Roberts Richard W. Methods of using sense and/or nonsense suppression to make nucleic acid-peptide display libraries containing peptides with unnatural amino acid residues
EP1567677A4 (fr) * 2002-11-22 2007-04-18 Marligen Biosciences Inc Detection d'enzymes proteases
US6931249B2 (en) 2003-01-23 2005-08-16 Motorola, Inc. Method and apparatus for a target-initiated handoff from a source cellular wireless network to a target non-cellular wireless network
CN108335750B (zh) * 2017-01-20 2022-08-09 华广生技股份有限公司 动态分析血糖值的方法、系统与计算机存储介质
CN111081325B (zh) * 2019-12-27 2023-12-12 医渡云（北京）技术有限公司 医疗数据处理方法与装置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2282593A1 (fr) 1997-03-31 1998-10-08 Du Pont Pharmaceuticals Company Indazoles d'urees cycliques utiles comme inhibiteurs de vih protease

Also Published As

Publication number Publication date
US6440659B1 (en) 2002-08-27
WO2001081926A1 (fr) 2001-11-01
US20020081571A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
AU1939801A (en) In situ bioreactors and methods of use thereof
AU2001267475A1 (en) Combinations of Enzyme Inhibitor-Containing Preparations and the use thereof
AU2001241474A1 (en) Biosensor compositions and methods of use
AU2002340415A1 (en) Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU6340600A (en) Telomerase inhibitors and methods of their use
HUP0402550A3 (en) Esters and amides as ppar-alpha agonists
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002320147A1 (en) Microdialysis probes and methods of use
AU2002230836A1 (en) Benzylamine derivatives and their use as thrombin inhibitors
AU2001233837A1 (en) Benzthiazoles as tnf and pde-iv inhibitors
AU2001270484A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU5758800A (en) Exclusive use display surface areas and persistently visible display of content with different display mode
IL143987A0 (en) New amidinobenzylamine derivatives and their use as thrombin inhibitors
AU2001253673A1 (en) Inhibitors of retroviral protease as inducers of reversible insulin resistance in vitro and in vivo
AU5693101A (en) New thiochromane derivatives and their use as thrombin inhibitors
AU2002365202A1 (en) Synthetic genes for malarial proteins and methods of use
AU2002306461A1 (en) In vivo delivery methods and compositions
AU2001255696A1 (en) Telomerase inhibitors and methods of their use
HUP0204376A3 (en) Novel invertase inhibitors and methods of use
AU2962200A (en) Use of agonists or antagonists of mip-3a in therapy
AU5220800A (en) Combination of mtp inhibitors and lipid reducers and the use thereof in medicaments
AU2002226986A1 (en) In vivo delivery methods and compositions